Q BioMed Inc. and ASDERA LLC have entered a licensing agreement providing Q BioMed with worldwide rights to ASDERA’s ASD-002, which is being developed to treat a rare pediatric nonverbal disorder. Q Biomed has global rights to develop and commercialize the drug in the rare pediatric disease market. Among the more than 60,000 U.S. children who develop autism spectrum disorders (ASD) every year, 20,000 become nonverbal or lose the ability to speak, potentially requiring assisted living.   ...